

Loreta Anesti Kondili

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8452728/publications.pdf>

Version: 2024-02-01

83
papers

6,266
citations

257101

24
h-index

79541

73
g-index

86
all docs

86
docs citations

86
times ranked

7790
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
3	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
4	Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. <i>Hepatology</i> , 1997, 26, 1006-1011.	3.6	375
5	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	3.7	237
6	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	3.7	208
7	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021, 74, 31-36.	1.8	189
8	Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. <i>Journal of Hepatology</i> , 2000, 33, 116-120.	1.8	127
9	Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. <i>Gut</i> , 2002, 50, 693-696.	6.1	91
10	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.4	56
11	Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2006, 25, 527-531.	1.3	48
12	The use of lamivudine for patients with acute hepatitis B (a series of cases). <i>Journal of Viral Hepatitis</i> , 2004, 11, 427-431.	1.0	43
13	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	1.1	42
14	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020, 40, 1545-1555.	1.9	37
15	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	1.1	37
16	Forecasting Hepatitis C liver disease burden on real-life data. Does the "hidden iceberg" matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	1.9	33
17	Correlation of alcohol consumption with liver histological features in non-cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 155-159.	0.8	31
18	Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. <i>Epidemics</i> , 2021, 34, 100442.	1.5	30

#	ARTICLE	IF	CITATIONS
19	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28
20	Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors. <i>Journal of Infection</i> , 2009, 59, 128-133.	1.7	27
21	Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy. <i>Infection</i> , 2013, 41, 69-76.	2.3	27
22	Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. , 1999, 58, 49-53.		26
23	Hepatitis B Virus Infection in Health Care Workers in Albania: a Country still Highly Endemic for HBV Infection. <i>Infection</i> , 2007, 35, 94-97.	2.3	26
24	High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. <i>Pediatric Infectious Disease Journal</i> , 1997, 16, 1049-1053.	1.1	26
25	Primary hepatocellular cancer in the explanted liver: Outcome of transplantation and risk factors for HCC recurrence. <i>European Journal of Surgical Oncology</i> , 2007, 33, 868-873.	0.5	25
26	Modeling cost-effectiveness and health gains of a universal versus prioritized hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	3.6	25
27	Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania. <i>Epidemiology and Infection</i> , 2006, 134, 95-101.	1.0	23
28	PIPER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. <i>Digestive and Liver Disease</i> , 2015, 47, 741-743.	0.4	23
29	Clinical and molecular characterization of chronic hepatitis B in Albania: A country that is still highly endemic for HBV infection. <i>Journal of Medical Virology</i> , 2005, 75, 20-26.	2.5	22
30	A unique HAV strain circulated in patients with acute HAV infection with different risk exposures in Tuscany, Italy. <i>Journal of Clinical Virology</i> , 2011, 50, 142-147.	1.6	20
31	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. <i>Digestive and Liver Disease</i> , 2022, 54, 237-242.	0.4	20
32	The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case-control study in Albania. <i>Epidemiology and Infection</i> , 1998, 121, 391-395.	1.0	19
33	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	1.8	19
34	The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. <i>Liver International</i> , 2021, 41, 934-948.	1.9	18
35	In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 187-194.	0.8	17
36	Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. <i>Liver International</i> , 2021, 41, 649-655.	1.9	16

#	ARTICLE	IF	CITATIONS
37	Will the COVID-19 pandemic affect HCV disease burden?. <i>Digestive and Liver Disease</i> , 2020, 52, 947-949.	0.4	15
38	Genotyping HCV isolates from Italy by type-specific PCR assay in the core region. <i>Research in Virology</i> , 1998, 149, 209-218.	0.7	14
39	<i>Helicobacter pylori</i> Seroprevalence in Selected Groups of Albanian Volunteers. <i>Infection</i> , 2008, 36, 345-350.	2.3	13
40	Acute hepatitis B in patients with or without underlying chronic HCV infection. <i>Journal of Infection</i> , 2008, 57, 152-157.	1.7	13
41	Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: A retrospective case-control study. <i>Digestive and Liver Disease</i> , 2014, 46, 726-730.	0.4	12
42	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019, 37, 255-266.	1.7	12
43	Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. <i>BMC Infectious Diseases</i> , 2021, 21, 413.	1.3	12
44	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	3.6	12
45	Prevalence of TT Virus in Healthy Children and Thalassemic Pediatric and Young Adult Patients. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2001, 33, 629-632.	0.9	10
46	Ultrasonography in the study of hepatocellular carcinoma in woodchucks chronically infected with WHV. <i>Laboratory Animals</i> , 2003, 37, 233-240.	0.5	10
47	Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. <i>Value in Health</i> , 2018, 21, 783-791.	0.1	10
48	Hepatitis B, C and Delta virus infections in Albanian patients with chronic liver disease: evaluation of possible changes during the last 10 years. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 167-171.	0.8	9
49	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. <i>Viruses</i> , 2022, 14, 1096.	1.5	9
50	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	1.9	8
51	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. <i>Liver International</i> , 2022, 42, 26-37.	1.9	8
52	Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine. <i>Vaccine</i> , 2007, 25, 4895-4902.	1.7	7
53	A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions. <i>BMC Infectious Diseases</i> , 2022, 22, 58.	1.3	7
54	Opportunistic co-screening for HCV and COVID-19 related services: A creative response with a need for thoughtful reflection. <i>Liver International</i> , 2022, 42, 960-962.	1.9	7

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 363-374.	0.7	6
56	Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 133-143.	1.0	6
57	GB Virus C/Hepatitis G Virus Exposure in Italian Pediatric and Young Adult Thalassaemic Patients. <i>Infection</i> , 2001, 29, 219-221.	2.3	5
58	Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated <sc>HCV</sc>-related condition in the real life practice. <i>Liver International</i> , 2018, 38, 183-183.	1.9	5
59	Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2020, 56, 325-329.	0.2	5
60	Effect of an immunogenic complex containing WHV viral particles and non-neutralizing anti-HBs antibodies on the outcome of WHV infection in woodchucks. <i>Journal of Medical Virology</i> , 2011, 83, 178-186.	2.5	4
61	Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana) Tj ETQq1 1 0.784314 rgBT /Overbo S618-S619.	1.8	4
62	Persistence of HCV-RNA in a blood donor with negative antibody assays. <i>Vox Sanguinis</i> , 1999, 76, 192-3.	0.7	4
63	Methodological issues in papers on IFN therapy: time for reappraisal. <i>Journal of Viral Hepatitis</i> , 2000, 7, 184-195.	1.0	3
64	Nucleic acid testing (NAT) for HCV RNA in Italian transfusion centres: An external quality assessment. <i>Journal of Clinical Virology</i> , 2008, 41, 277-282.	1.6	3
65	Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients. <i>Infectious Agents and Cancer</i> , 2021, 16, 5.	1.2	3
66	Molecular characterisation of SENV and TTV infections in hepatopathic liver-transplant patients. <i>Archives of Virology</i> , 2004, 149, 1423-33.	0.9	2
67	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. <i>Antiviral Therapy</i> , 2020, 25, 73-81.	0.6	2
68	Parent training education program: a pilot study, involving families of children with Prader-Willi syndrome. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2016, 52, 428-433.	0.2	2
69	Hepatitis B virus core gene sequence in patients with chronic hepatitis B from an HBV hyperendemic area. <i>Journal of Hepatology</i> , 2002, 36, 224.	1.8	1
70	Woodchuck hepatitis virus core gene deletions and proliferative responses of peripheral blood mononuclear cells stimulated by an immunodominant epitope: a viral immune escape in the woodchuck model of chronic hepatitis B?. <i>Archives of Virology</i> , 2015, 160, 1065-1073.	0.9	1
71	HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, e6-e7.	0.4	1
72	Risk factors among coronary heart disease patients in the context of the Albanian paradox. <i>Anatolian Journal of Cardiology</i> , 2012, 12, 82.	0.4	1

#	ARTICLE	IF	CITATIONS
73	[406] RAPID INSURGENGE OF A VIRAL RESISTANT MUTANT IN WHV CHRONICALLY INFECTED WOODCHUCKS TREATED WITH LAMIVUDINE AND A PRE-S/S CHO-DERIVED HEPATITIS B VIRUS VACCINE. Journal of Hepatology, 2007, 46, S156.	1.8	0
74	Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study. Digestive and Liver Disease, 2015, 47, e224-e225.	0.4	0
75	HCV-Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study. Journal of Hepatology, 2016, 64, S619.	1.8	0
76	Clinical and virological characteristics of HIV and HCV co-infected versus HCV monoinfected patients: A real-life evaluation in the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti) Tj ETQq0 0 0 r g BT / Overlock 10 T		
77	Forecasting liver disease burden. Digestive and Liver Disease, 2018, 50, 10-11.	0.4	0
78	Epidemiological and economic evaluations according to DAA treatment access: an interim evaluation based on PITER cohort data. Journal of Virus Eradication, 2018, 4, 25-26.	0.3	0
79	THU-397-Screening strategies for hepatitis C virus elimination in Italy. Journal of Hepatology, 2019, 70, e330.	1.8	0
80	THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort. Journal of Hepatology, 2019, 70, e294.	1.8	0
81	Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a prospective analysis in the PITER cohort. Digestive and Liver Disease, 2019, 51, e61.	0.4	0
82	The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort. Journal of Hepatology, 2020, 73, S616-S617.	1.8	0
83	Reply. Hepatology, 2022, 76, E11-E12.	3.6	0